Evidence map›Paper›PMID 37165035›Full record

ArticleScientific reports2023

Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning.

Ahmet Said Kucukkaya, Tal Zeevi, Nathan Xianming Chai, Rajiv Raju, Stefan Philipp Haider, Mohamed Elbanan, Alexandra Petukhova-Greenstein, MingDe Lin, John Onofrey, Michal Nowak and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ahmet Said KucukkayaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Tal ZeeviDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Nathan Xianming ChaiDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Rajiv RajuDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Stefan Philipp HaiderDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Mohamed ElbananDepartment of Diagnostic Radiology, Bridgeport Hospital, Yale New Haven Health System, 267 Grant Street, Bridgeport, CT, 06610, USA.
Alexandra Petukhova-GreensteinDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
MingDe LinDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
John OnofreyDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Michal NowakDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Kirsten CooperDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Elizabeth ThomasDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Jessica SantanaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Bernhard GebauerInstitute of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
David MulliganTransplantation and Immunology, Department of Surgery, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Lawrence StaibDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA.
Ramesh BatraTransplantation and Immunology, Department of Surgery, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Julius ChapiroDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, 330 Cedar Street, New Haven, CT, 06520-8042, USA. julius.chapiro@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver CancerR01CA206180 · NCI · YALE UNIVERSITY · PI CHAPIRO, JULIUS, DUNCAN, JAMES S · 2016 to 2025
$6.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA206180NIH HHS R01CA206180
6 · The paper itself

Abstract

Tumor recurrence affects up to 70% of early-stage hepatocellular carcinoma (HCC) patients, depending on treatment option. Deep learning algorithms allow in-depth exploration of imaging data to discover imaging features that may be predictive of recurrence. This study explored the use of convolutional neural networks (CNN) to predict HCC recurrence in patients with early-stage HCC from pre-treatment magnetic resonance (MR) images. This retrospective study included 120 patients with early-stage HCC. Pre-treatment MR images were fed into a machine learning pipeline (VGG16 and XGBoost) to predict recurrence within six different time frames (range 1-6 years). Model performance was evaluated with the area under the receiver operating characteristic curves (AUC-ROC). After prediction, the model's clinical relevance was evaluated using Kaplan-Meier analysis with recurrence-free survival (RFS) as the endpoint. Of 120 patients, 44 had disease recurrence after therapy. Six different models performed with AUC values between 0.71 to 0.85. In Kaplan-Meier analysis, five of six models obtained statistical significance when predicting RFS (log-rank p < 0.05). Our proof-of-concept study indicates that deep learning algorithms can be utilized to predict early-stage HCC recurrence. Successful identification of high-risk recurrence candidates may help optimize follow-up imaging and improve long-term outcomes post-treatment.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansMachine LearningMagnetic Resonance ImagingNeoplasm Recurrence, LocalRetrospective Studies

Identifiers

PMID37165035
PMCPMC10172370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.